Contract development and manufacturing organization, Alliance Contract Pharma (ACP), said one of its clients received FDA approval for the first twice-daily ocular corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.   ACP supported the development of this product through a range of phases: formulation development, clinical supply, process validation, FDA inspection and approval, and launch.   “The most rewarding aspect of the yea...